Business
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea\nNEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2025, being held September 17 - 21, 2025, in San Diego, California. Details of the presentations are as follows: Major Depressive Disorder Title: Initiating Auvelity® (dextromethorphan 45 mg-bupropion 105 mg) in Patients with Major Depressive Disorder: Expert Panel Consensus RecommendationsPresentation Date and Time: Friday, September 19, 1:30 - 3:00 p.m. and 6:00 - 7:15 p.m.; Saturday, September 20, 1:30 - 3:00 p.m. PTLead Author: Anita H. Clayton, MD, Professor and Chair of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of MedicinePoster Number: 184 Alzheimer’s Disease Agitation Title: Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled StudyPresentation Date and Time: Friday, September 19, 1:30 - 3:00 p.m. and 6:00 - 7:15 p.m.; Saturday, September 20, 1:30 - 3:00 p.m. PTLead Author: Jeffrey Cummings, MD, ScD, Vice Chair of Research, UNLV Department of Brain HealthPoster Number: 47 Narcolepsy Title: Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY TrialPresentation Date and Time: Friday, September 19, 1:30 - 3:00 p.m. and 6:00 - 7:15 p.m.; Saturday, September 20, 1:30 - 3:00 p.m. PTLead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NYPoster Number: 118 Title: ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in NarcolepsyPresentation Date and Time: Friday, September 19, 1:30 - 3:00 p.m. and 6:00 - 7:15 p.m.; Saturday, September 20, 1:30 - 3:00 p.m. PTLead Author: Richard Bogan, MD, FCCP, FAASM, Associate Clinical Professor at the University of South Carolina School of M...